GILD vs. MRNA, SGEN, TECH, AMGN, VRTX, REGN, BIIB, ALNY, BMRN, and NBIX
Should you be buying Gilead Sciences stock or one of its competitors? The main competitors of Gilead Sciences include Moderna (MRNA), Seagen (SGEN), Bio-Techne (TECH), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), and Neurocrine Biosciences (NBIX). These companies are all part of the "medical" sector.
Moderna (NASDAQ:MRNA) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, community ranking, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.
75.3% of Moderna shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 15.7% of Moderna shares are owned by insiders. Comparatively, 0.2% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Moderna had 16 more articles in the media than Gilead Sciences. MarketBeat recorded 40 mentions for Moderna and 24 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 0.49 beat Moderna's score of 0.32 indicating that Moderna is being referred to more favorably in the media.
Moderna has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.
Moderna presently has a consensus target price of $126.46, indicating a potential downside of 11.29%. Gilead Sciences has a consensus target price of $83.69, indicating a potential upside of 30.21%. Given Moderna's stronger consensus rating and higher probable upside, analysts clearly believe Gilead Sciences is more favorable than Moderna.
Gilead Sciences has a net margin of 1.76% compared to Gilead Sciences' net margin of -115.82%. Moderna's return on equity of 24.34% beat Gilead Sciences' return on equity.
Gilead Sciences has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Gilead Sciences received 2251 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 77.37% of users gave Gilead Sciences an outperform vote while only 57.77% of users gave Moderna an outperform vote.
Summary
Gilead Sciences beats Moderna on 12 of the 17 factors compared between the two stocks.
Get Gilead Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GILD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gilead Sciences Competitors List
Related Companies and Tools
